Since centenarians typically escape cardiovascular disease.

‘Since centenarians typically escape cardiovascular disease, diabetes and other age-related diseases, we suspected these most senior of the seniors may have to help gene variants they reach old age,’said Dr. Nir Barzilai, Institute for Aging Research at Einstein and senior author on the paper ‘If so, then these genotypes should occur with higher frequency in centenarians than in the rest of us. ‘.

In an earlier study, the researchers had found that centenarians ‘ LDL and larger than normal larger than normal, so these were also measured.. The researchers looked for genetic evidence of longevity in a group of 214 Ashkenazi Jews have passed or nearly reached 100 years of age. In the 4th April issue of PLoS Biology , they report that a certain genetic profile, or genotype, was associated with longevity and cardiovascular health, lower incidence of hypertension and healthy insulin metabolism.

Kline stressed caution in view of the results of the study show the difference in asthma diagnosis between the two schools.Option arrangement And Resolvyx Pharmaceuticals proclaim an alliance of Ophthalmology – famous Celtic Therapeutics Holdings LP , a follower of company for Celtic Pharma , and Resolvyx Pharmaceuticals that you into an option agreement relating Resolvyx have entered RX-10045, a late-stage program for the treating dry eye syndrome, and other ophthalmic conditions. Associated with the RX-10045 option agreement, Celtic Therapeutics purchased a note converts into Resolvyx equity.

Resolvins a recently discovered Family reviews of naturally occurring, a small molecule lipid mediators, of dry eye specifically for a wide array of diseases. Resolvins proving to be extremely powerful and effective over a broad range of pre-clinical models for asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and disease of the retina, among others. Source: Celtic Pharmaceutical Holdings L.. Under terms of the option agreement, Celtic Therapeutics on an exclusive option to acquire and license rights to Resolvyx of the RX-10045, in all the eyes indications.